Figure 2From: AAV-mediated gene therapy for metabolic diseases: dosage and reapplication studies in the molybdenum cofactor deficiency modelDe-escalations studies of AAV1/2-MOCS1 delivery. Survival of Mocs1-deficient mice injected i.v. on day 40 after birth with various amounts of AAV-MOCS1. Group A (blue) was injected with 4 × 109 tu (n = 2). Group B (red) received 1.5 × 108 tu AAV-MOCS1 (n = 8). Group C (green) received a single injection containing 4 × 108 tu (n = 12).Back to article page